Press Releases Sanofi

Equities

SAN

FR0000120578

Real-time Euronext Paris Other stock markets 10:57:24 2024-05-20 am EDT			5-day change	1st Jan Change
89.42 ^EUR	+0.28%		-3.57%	-0.40%

02:52pm	Shah Capital ends campaign against Novavax board after Sanofi deal	RE
12:36pm	Shah Capital withdraws campaign against Novavax directors after Sanofi deal	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enabling The "Full Scope" Of Claims In View Of The Supreme Court's Decision In Amgen	May. 13	AQ
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines	May. 13	AQ
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights	May. 13	AQ
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty	May. 13	GL
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines	May. 10	GL
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations	May. 02	GL
Press Release: Annual General Meeting of April 30, 2024	Apr. 30	GL
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024	Apr. 30	AQ
Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases	Apr. 26	PU
Sanofi Q1 robust 7% sales growth driven by launches, underpins full-year guidance	Apr. 26	AQ
Sanofi: Q1 Earnings Snapshot	Apr. 25	AQ
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance	Apr. 25	GL
AusBiotech announces incoming CEO	Apr. 24	AQ
Sanofi - Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 24	AQ
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 23	GL
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 23	AQ
The 2023 Pharmaceutical Patent Review	Apr. 17	AQ
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis	Apr. 17	GL
INNATE PHARMA ANNOUNCES ADVANCEMENT OF SANOFI-DEVELOPED NK CELL ENGAGER SAR443579/IPH6101 PROGRESSING TO PHASE 2 FOR BLOOD CANCER PATIENTS	Apr. 16	AQ
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents	Apr. 08	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST